
Dr Desai on the PATINA Study of a Palbociclib-Based Regimen in HR+/HER2+ Metastatic Breast Cancer
“In this trial, at that juncture of maintenance therapy, patients were [randomly assigned] to [receive trastuzumab, pertuzumab], and endocrine therapy with or without palbociclib. What this study showed was that the addition of palbociclib [to this regimen …